239 related articles for article (PubMed ID: 37433281)
1. Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM; Chadwick JA; Owen RP; White MJ; Kaplinsky J; Peneva I; Frangou A; Xie PF; Chang J; Roth A; Amess B; James SA; Rei M; Fuchs HS; McCann KJ; Omiyale AO; Jacobs BA; Lord SR; Norris-Bulpitt S; Dobbie ST; Griffiths L; Ramirez KA; Ricciardi T; Macri MJ; Ryan A; Venhaus RR; Van den Eynde BJ; Karydis I; Schuster-Böckler B; Middleton MR; Lu X;
Cancer Cell; 2023 Jul; 41(7):1222-1241.e7. PubMed ID: 37433281
[TBL] [Abstract][Full Text] [Related]
2. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract][Full Text] [Related]
3. An Immune-Related Gene Signature for Predicting Survival and Immunotherapy Efficacy in Esophageal Adenocarcinoma.
Yang C; Cao F; He Y
Med Sci Monit; 2023 Aug; 29():e940157. PubMed ID: 37632137
[TBL] [Abstract][Full Text] [Related]
4. Development of immune gene pair-based signature predictive of prognosis and immunotherapy in esophageal cancer.
Cao K; Ma T; Ling X; Liu M; Jiang X; Ma K; Zhu J; Ma J
Ann Transl Med; 2021 Oct; 9(20):1591. PubMed ID: 34790797
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
6. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
7. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma.
Wang Z; Wang X; Xu Y; Li J; Zhang X; Peng Z; Hu Y; Zhao X; Dong K; Zhang B; Gao C; Zhao X; Chen H; Cai J; Bai Y; Sun Y; Shen L
BMC Med; 2022 Apr; 20(1):133. PubMed ID: 35443723
[TBL] [Abstract][Full Text] [Related]
8. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
9. Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response.
Ling C; Zhou X; Gao Y; Sui X
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631431
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.
Zhang Z; Wang ZX; Chen YX; Wu HX; Yin L; Zhao Q; Luo HY; Zeng ZL; Qiu MZ; Xu RH
Genome Med; 2022 Apr; 14(1):45. PubMed ID: 35488273
[TBL] [Abstract][Full Text] [Related]
11. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.
Yoon HH; Jin Z; Kour O; Kankeu Fonkoua LA; Shitara K; Gibson MK; Prokop LJ; Moehler M; Kang YK; Shi Q; Ajani JA
JAMA Oncol; 2022 Oct; 8(10):1456-1465. PubMed ID: 36006624
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.
Bockorny B; Pectasides E
Future Oncol; 2016 Aug; 12(15):1833-46. PubMed ID: 27166503
[TBL] [Abstract][Full Text] [Related]
13. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy in Hepatogastroenterology - update 2022: efficacy and immune-related adverse events].
Krimmel L; Quante M; Bengsch B
Dtsch Med Wochenschr; 2023 Mar; 148(6):294-300. PubMed ID: 36878227
[TBL] [Abstract][Full Text] [Related]
15. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
[TBL] [Abstract][Full Text] [Related]
16. Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.
Long J; Wang D; Yang X; Wang A; Lin Y; Zheng M; Zhang H; Sang X; Wang H; Hu K; Zhao H
BMC Med; 2021 Jul; 19(1):154. PubMed ID: 34284787
[TBL] [Abstract][Full Text] [Related]
17. Novel Aberrations Uncovered in Barrett's Esophagus and Esophageal Adenocarcinoma Using Whole Transcriptome Sequencing.
Maag JLV; Fisher OM; Levert-Mignon A; Kaczorowski DC; Thomas ML; Hussey DJ; Watson DI; Wettstein A; Bobryshev YV; Edwards M; Dinger ME; Lord RV
Mol Cancer Res; 2017 Nov; 15(11):1558-1569. PubMed ID: 28751461
[TBL] [Abstract][Full Text] [Related]
18. Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy.
Kumagai S; Koyama S; Shitara K
Cancer Cell; 2023 Jul; 41(7):1199-1201. PubMed ID: 37433280
[TBL] [Abstract][Full Text] [Related]
19. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
